STOCK TITAN
  1. Home
  2. GNBT

Generex Biotechnology (GNBT) Stock Price, News & Analysis

GNBT
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
91 178 sessions, December 31, 2021 to October 27, 2022
Largest daily move
+1566.7% close of March 2, 2022
1-month change
-14.3% closing prices, September 27, 2022 to October 27, 2022

Company Description

GNBT declined 99.0% in the year to October 27, 2022. The last closing price was $0.0006.

This page collects what Stock Titan holds for GNBT, including price data and latest news.

Stock Performance

Chart
$0.0006
No recent trading
Last close: October 27, 2022
-99%
Year to October 27, 2022
-
Market Cap
-
Shares outstanding

Generex Biotechnology (GNBT) closed at $0.0006 on October 27, 2022. In the year to October 27, 2022, the price lost 99.0%.

See what a $1,000 investment in GNBT would be worth today

Average down calculator for GNBT

GNBT Metrics & Rankings

October 2022
-14.3%
—
2022
-99.0%
—

Price returns through October 27, 2022. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
-99.57%

Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix from The Malaysian Ministry of Health, its country’s equivalent to the U.S. FDA

fda approval
-99.57%

NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm

-99.57%

Generex Biotechnology Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Patient Monitoring (RPM) Services

-99.57%

Generex Posts Recording of May 6 Shareholder Conference Call Highlighting its Ii-Key COVID Complete Vaccine™ and its Go-Forward Plans for Revenue Producing Assets

conferences covid-19
-99.57%

Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services

-99.57%

Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement

partnership covid-19
-99.57%

Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM

conferences
-99.57%

Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Agreement with Nexgen Medical for Distribution of Excellagen® Wound Conforming Matrix in Malaysia

-99.57%

Generex Provides Update on its Ii-Key COVID-19 Complete Vaccine Program: Advancing Global Development

covid-19
-99.57%

NuGenerex Immuno-Oncology Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission

fda approval

Generex Biotechnology has 10 recent news articles. Of the recent coverage, 0 articles coincided with positive price movement and 10 with negative movement. Key topics include fda approval, conferences, covid-19, partnership. View all GNBT news →

SEC Filings

No SEC filings available for GNBT.

Frequently Asked Questions

Generex Biotechnology (GNBT) has no recent trading. Its last close was $0.0006 on October 27, 2022.